014570 — Korean Drug Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩70bn
- KR₩54bn
- KR₩81bn
- 82
- 77
- 24
- 70
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 55,529 | 66,789 | 74,466 | 79,984 | 81,375 |
Cost of Revenue | |||||
Gross Profit | 21,308 | 28,689 | 31,065 | 34,517 | 37,350 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 52,113 | 56,290 | 63,200 | 65,655 | 63,349 |
Operating Profit | 3,416 | 10,500 | 11,266 | 14,329 | 18,026 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4,450 | 9,240 | 11,321 | 14,685 | 8,265 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,895 | 7,360 | 9,042 | 11,809 | -4,917 |
Net Income Before Extraordinary Items | |||||
Net Income | 3,895 | 7,360 | 9,042 | 11,809 | -4,917 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3,895 | 7,360 | 9,042 | 11,809 | -4,917 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 353 | 717 | 828 | 1,095 | -456 |
Dividends per Share |